

## **NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

### **Equality and health inequality impact assessment**

## **Atogepant for treating migraine**

### **Final draft guidance (when issued)**

- 1 Have any potential equality or health inequality issues been raised during scoping or in the submissions, patient expert statements or academic report? If so, how has the committee addressed these?**

Stakeholder submissions for the cost-comparison noted:

- Access to treatments like calcitonin gene-related peptide (CGRP) varies by location causing inequity to access. There is a need for GREEN formulary status for these treatments to allow primary care access to help reduce disparities.
- There are concerns about stigma and discrimination, especially among women and people from mixed or multiple ethnic minority groups
- People on low-income also report living with migraine impacts on job security and career progression.

Chair and vice chair acknowledged the issues and noted that access was not associated with a protected characteristic. They also considered whether its recommendations could affect health inequalities associated with socioeconomic factors. They considered they had not been presented with evidence that people in more deprived areas are at greater risk of becoming disabled by migraine. They also considered that NICE's methods do not include productivity costs in its analyses. The chair and vice chair noted that the

recommendations will not result in any equality concerns and no specific adjustments were needed.

**2 Have any additional potential equality or health inequality issues been identified by the committee? If so, how has the committee addressed these?**

No

**3 If the recommendations have changed after consultation, do the updated recommendations make it more difficult for a specific group to access the technology than other groups? If so, what are the barriers to, or difficulties with, access for this group?**

Not applicable

**4 If the recommendations have changed after consultation, has the committee made any other reasonable adjustments in the recommendations for the equality issues identified? That is, have any adjustments to the recommendations been made to remove or alleviate barriers to, or difficulties with, access to the technology needed to fulfil NICE's obligations to promote equality.**

Not applicable

**5 Has the committee taken into consideration the health inequality issues in its decision-making? If so, how was this done?**

The committee was not presented with evidence that people in more deprived areas are at greater risk of becoming disabled by migraine. No other health inequalities were presented or considered by committee.

**6 Have the committee’s considerations of equality and health inequality issues been described in the final draft guidance? If so, where?**

No as no equality issues identified and the final draft guidance includes only a brief overview of why these recommendations were made.

**Approved by senior responsible officer: Elizabeth Bell**

**Date: 20/05/2026**